Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Allen
Unknown Affiliation
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Peran SGLT2i terhadap Risiko Kardiorenal Pasien dengan atau Tanpa Diabetes Melitus Tipe 2 Allen
Cermin Dunia Kedokteran Vol 51 No 2 (2024): Dermatologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i2.873

Abstract

Sodium-glucose Co-transporter 2 inhibitor (SGLT2i) is one of the antidiabetic classes recommended for patients with heart and kidney problems. Evidence-based studies show the benefits of SGLT2i extend to heart, kidney, or other metabolic diseases in patients without diabetes mellitus.
Co-Authors